This French Nursing Home Accepts Inmates Others Won't
Like the general population, France's prison population is aging. In 2019, nearly 2600 inmates were over the age of 60, and close to 500 were over 70. According to the French Prison Administration Directorate (DAP), 115 of these individuals were classified as dependent, and 430 were living with physical disabilities.
Despite these needs, very few healthcare facilities in France are equipped to accommodate older, dependent former inmates. Currently, only two nursing homes accept individuals with a history of incarceration. One of them is the Saint Barthélemy nursing home in Marseille, affiliated with the Saint John of God Foundation. Its director, Olivier Quenette, spoke with Journal International de Medecine (JIM) , a Medscape Network platform, about the challenges and responsibilities involved in caring for this particularly vulnerable group.
How did your nursing home come to care for individuals coming out of the prison system? Is there a link to the philosophy of the Foundation that supports your facility?
It happened by chance. We were approached by a family member of a 61-year-old man who had just been released from prison and had no housing solution. We agreed to take him in.
The Foundation's philosophy is to support the most vulnerable — those who are invisible or without options. We're committed to unconditional acceptance, so we responded positively to what was, in this case, an urgent request.
Did the idea of accepting incarcerated individuals develop gradually from there?
Absolutely. In 2005, we visited the Saint John of God facility in Austria, which had created a correctional unit within a hospital. That inspired us to consider the needs of aging people in prison. We started to study the issue and built relationships with the prison system to understand how it works — its language, procedures, and requirements — to be able to integrate these individuals appropriately.
How many incarcerated or formerly incarcerated individuals do you currently care for? What is their legal status?
As of our latest count in June 2024, we had admitted 29 people, including two women, with ages ranging from 54.5 to 89.7 years — an average age of 69.9. Fourteen were on modified sentences with judicial oversight, three were on parole with electronic monitoring, and seven had medical sentence suspensions. Only one was released without support.
How do you ensure anonymity for residents with a history of incarceration?
We've chosen to uphold a right to be forgotten. What matters to us is that the individual has either served their sentence or is in the process of doing so. We do not share the reasons for a resident's incarceration with the care team. This is an ethical decision. It's up to the resident to disclose their background, if and when they choose.
Naturally, in today's digital age, media reports about certain cases are easy to find. We've encountered such situations. But after more than 15 years of admitting former inmates, this is no longer a sensitive issue within our facility. We treat each person as an individual — not as someone defined by a past offense. Others may choose to look into a resident's background, but for us, it holds no greater weight than any other part of their personal history. We treat it as confidential, much like medical information.
Are there specific medical characteristics that distinguish incarcerated or formerly incarcerated residents from others in your facility?
Our nursing home has a somewhat specialized profile; we primarily care for individuals who have experienced homelessness or who live with mental health conditions. Of our 245 beds, the majority are occupied by residents with nontraditional or complex life histories. The current average age is 74, and approximately 60% of residents are men. Most are enrolled in public social assistance programs.
One of the key challenges with formerly incarcerated residents is helping them unlearn institutional behaviors developed in prison and relearn how to live independently. We recognized early on that this group requires more frequent and intensive psychological support, as they tend to experience higher levels of anxiety. This is particularly true for younger residents, especially those under the age of 65, who also benefit from more structured daily activities.
To support their reintegration, we offer paid, meaningful activities that carry therapeutic, occupational, and social value within the facility's community. We also maintain close collaboration with correctional social workers (known in France as CPIPs, Conseillers Pénitentiaires d'Insertion et de Probation), who visit monthly to meet with both the former inmates and staff.
We've successfully supported the reintegration of several former residents; four have transitioned to independent living. These transitions always take place following a period of judicial supervision, but each resident leads the process, and we provide support every step of the way.
What psychological and psychiatric support do you provide?
Some residents have psychiatric conditions. We rely on private psychiatrists who also care for our other residents, and we ensure follow-up. Our in-house psychologists work closely with these individuals, especially during the admission period and the first few months. Some residents are also under mandatory psychiatric follow-up ordered during incarceration.
How do you coordinate medical care and judicial monitoring — for example, for residents with electronic ankle monitors?
Their medical care is the same as for any other resident. With their consent, they are assigned a private physician who manages their care, appointments, and testing. We handle transport logistics if needed. One resident took 2 years before leaving the facility, so we support them in rebuilding autonomy.
Those with ankle monitors are allowed to leave their rooms during specific times, managed in coordination with their probation officer.
Nursing homes often report difficulties in hiring healthcare staff. Does your facility face these challenges?
The healthcare labor market in our sector is undeniably tight. We face recruitment challenges in certain roles, particularly when it comes to coordinating physicians — a difficulty reported by more than 30% of nursing homes in France. However, for nursing and nursing assistant positions, we are currently able to meet about 95% of our staffing needs. While we are not experiencing acute shortages, there is ongoing pressure, and we must continuously recruit to anticipate potential vacancies and ensure continuity of care.
Have your staff received specific training to care for current or former inmates? Have any raised concerns?
No specific training has been provided for caring for formerly incarcerated individuals. As I mentioned, we focus first on the resident's primary condition — whether that be mental illness, physical illness, or a state of dependency. In our experience, residents with severe psychiatric histories — particularly those recently discharged from psychiatric hospitals — often present greater care challenges than former inmates.
That said, we do offer targeted training on geriatric mental health, though not programs specifically focused on the needs of former prisoners.
Regarding staff concerns, we addressed them through discussions with our internal multidisciplinary ethics committee. We made a deliberate choice not to create dedicated units for former inmates. Instead, they are integrated across all units. This approach has worked well. Even during our initial admissions, there were some questions, but no significant issues arose.
In principle, any prisoner can be granted release for medical reasons or if they are over the age of 70. Is this law effectively applied?
Not at all. As I recall, this provision was introduced in 2014 by then-Justice Minister Christiane Taubira. But in reality, many incarcerated individuals over 70 are unable to access release because no care facility is available to receive them. So, despite being on the books, the law remains difficult to apply in practice.
Medical parole is granted by a sentencing judge, based on clinical evaluations. However, it only becomes a viable option if a long-term care facility is willing and able to admit the individual. According to the DAP, roughly 80-90 older inmates in France each year would meet the criteria for such release. That is a relatively small number considering the total nursing home capacity nationwide. But the fear of recidivism, especially involving individuals convicted of sexual offenses, remains the primary barrier to placement.
France currently has only two nursing homes that accept former inmates — yours and one in Cuiseaux. Should more facilities follow this model? What are the barriers?
In addition to the facility in Cuiseaux, a nursing home in the Ardennes began accepting former inmates 2 years ago, and the French Red Cross has also shown interest in participating.
Progress is being made, but it remains slow and limited. The biggest barrier is stigma: the fear that someone who has committed a crime may reoffend. Facilities are concerned about how families will react, whether there are safety risks for other residents, and what staff will think.
These fears continue to prevent many nursing homes from accepting former inmates. Yet these individuals are often seriously ill and no longer capable of living independently in a prison setting. In some cases, their living conditions behind bars may even be incompatible with basic human dignity.
In collaboration with the Ministry of Justice and the DAP, we've presented our model to national networks of nursing home directors to encourage broader participation. I've also met with two large foundations that have committed to supporting these efforts. The idea is starting to gain traction, but significant challenges remain.
For older, dependent inmates who remain in prison, what improvements are needed in their medical care?
At a minimum, prisons need architectural modifications to better accommodate individuals with physical dependency. In addition, access to in-home nursing services must be significantly improved within prisons and detention facilities.
While a few pilot programs exist, the response time for initiating care is approximately four times longer than in the general population. The main barrier is financial.
In my view, the most practical solution would be for every nursing home in France to commit to accepting at least one inmate per year. If just 90 facilities nationwide did so, we could resolve this public health challenge.
At our facility, for example, we currently house former inmates from Bapaume Prison near Lille. Before being accepted here, they were denied admission by 40-50 nursing homes in their local region.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
24 minutes ago
- Health Line
Stages of Crohn's Disease
Key takeaways Crohn's disease symptoms can be mild, moderate, or severe. It's a progressive disease, but its stages are hard to determine because each person's condition progresses differently. The earlier you treat and manage Crohn's, the more likely you are to reduce your chance of developing more severe symptoms. There's no cure for Crohn's disease, but medications and lifestyle changes can help manage the condition. This is why it's crucial to identify the disease when symptoms are still mild. Crohn's disease is a type of inflammatory bowel disease (IBD). It's considered a chronic condition, which means that you'll have it for your entire life. The exact cause of Crohn's is unknown. It most often develops in your late teens or 20s. Crohn's disease is marked by inflammation of the gastrointestinal (GI) tract. The inflammation can appear anywhere in the GI tract, from the mouth to the anus. What are the stages of Crohn's disease? Crohn's is a progressive disease that starts with mild symptoms and gradually gets worse. With mild to moderate Crohn's, you may experience diarrhea or abdominal pain, but you won't experience other symptoms or complications. You're able to move, eat, and drink as normal, and the disease has a minimal impact on your quality of life. In some cases, you won't even require treatment. If you have moderate to severe Crohn's disease, you may experience diarrhea or abdominal pain, as well as additional symptoms and complications, such as fever or anemia. If your Crohn's is severe, you might be in constant pain and discomfort, and you may need to use the bathroom frequently. That said, it's difficult to classify Crohn's disease into stages because people tend to experience ups and downs in symptoms. What progression looks like can be different for each person, and treatment can affect your outlook. How quickly does Crohn's disease progress? Over time, Crohn's can cause damage to the intestines and lead to potential complications such as strictures, fistulas, and abscesses. Stricture means that a portion of the intestine becomes narrower due to scar tissue on its wall. While there's no time frame for how long it would take for such complications to develop, there are risk factors that may speed up progression. These include: being under 30 years old having a history of smoking having ulcers found in a colonoscopy having the long bowel segments affected by the disease having anal inflammation having symptoms that go beyond the intestinal system, such as in the eyes, skin, liver, or joints having a history of bowel resections At diagnosis, 10% of people already have strictures, and an additional 15% to 20% will develop them within the next 10 to 20 years. Five types of Crohn's disease Progression may also depend on the type of Crohn's disease you have. These are: ileocolitis ileitis gastroduodenal Crohn's disease diffuse jejunoileitis Crohn's colitis Crohn's disease progression patterns The patterns by which Crohn's might progress are: Chronic relapsing: With this progression type, you typically experience at least 12 months of remission before experiencing a flare. Common symptoms of a Crohn's disease flare-up may include diarrhea, abdominal pain, weight loss, blood in stool, and fatigue. Remission: Remission means that your symptoms improve or disappear completely. Various studies show most people will relapse within 8 years of diagnosis, with a 43% to 45% remission rate after 10 years. But if you stay in remission for a year, there's an 80% chance remission will continue for the next year. Improved and stable: This is when your condition has progressed to having no symptoms and has remained this way, though signs of the disease might still show up on tests. Chronic refractory: This means you continue to show symptoms without any breaks or remission. About 10% to 15% of people with Crohn's experience a chronic refractory disease course. That said, even different people living with the same Crohn's pattern might progress differently. Genetics, type of treatment, and surgery are also factors that may affect which disease course you follow. The earlier you treat and manage Crohn's, the more likely you are to reduce your chance of developing more severe symptoms. What is the life expectancy of someone with Crohn's disease? There's no cure for Crohn's disease, though many people can live fulfilling lives with long periods of remission. That said, although there's been an increase in life expectancy for people living with inflammatory bowel diseases (IBDs), the life expectancy of Crohn's is still lower compared to those without IBDs for both males and females. When Crohn's causes complications, it can, in rare cases, lead to death. Common causes of death include cancer, heart disease, and infection. What are the early symptoms of Crohn's disease? In Crohn's disease, healthy cells in the GI tract attack themselves, causing inflammation. As a result, you'll likely experience a range of symptoms. Early signs of Crohn's disease include: frequent cramps ongoing abdominal pain frequent diarrhea bloody stools unintentional weight loss As the disease progresses, you may start feeling fatigued and even develop anemia. You may also experience nausea from constant irritation of the GI tract. In addition, you may start experiencing symptoms outside of the GI tract. These symptoms include: eye pain fever joint inflammation and pain red skin rashes and bumps mouth sores Early diagnosis is important to help prevent damage to the intestines. If you experience these symptoms and have a family history of Crohn's, you should ask your doctor for testing. How is Crohn's disease treated and managed? Medications can treat inflammation and stop your body from attacking its own cells. As your symptoms progress, your gastroenterologist may also recommend occasional bowel rest. However, not all doctors agree with this measure. A bowel rest involves a strict diet of only liquids for a few days. The purpose is to let the GI tract heal from inflammation and essentially take a break. To prevent malnutrition, you may need an IV. Talk with your doctor before switching to a liquid diet. Following this, your doctor may follow a special Crohn's diet and take supplements. You also may need to take pain medication. Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin), as these can make Crohn's worse. Instead, ask your doctor if you can safely take acetaminophen (Tylenol). You may need surgery if your symptoms become life threatening. Around 67% to 75% of all people with Crohn's will eventually need surgery, according to the Crohn's & Colitis Foundation. Surgery can't cure the disease, but it may help repair severely damaged tissues and remove blockages.
Health Line
24 minutes ago
- Health Line
Current and Breakthrough Treatments for Chronic Lymphocytic Leukemia (CLL)
Key takeaways Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, many treatment options are available that can help people go into remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. While there's no cure for CLL yet, breakthroughs in the field are on the horizon. A large number of approaches are under investigation to treat CLL, including drug combinations and CAR T-cell therapy. Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow-growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, there are many available treatment options that can help people achieve remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. The exact treatment option that you'll receive depends on a variety of factors. This includes: whether your CLL is symptomatic the stage of the CLL, based on results of blood tests and a physical exam your age your overall health While there's no cure for CLL yet, breakthroughs in the field are on the horizon. Treatments for low risk CLL Doctors typically stage CLL using a system called the Rai system. Low risk CLL describes people who fall in 'stage 0' under the Rai system. In stage 0, the lymph nodes, spleen, and liver are not enlarged. Red blood cell and platelet counts are also near normal. If you have low risk CLL, your doctor (usually a hematologist or oncologist) will likely advise you to ' watch and wait ' for symptoms. This approach is also called active surveillance. Someone with low risk CLL may not need further treatment for many years. Some people will never need treatment. You'll still need to see a doctor for regular checkups and lab tests. Treatments for intermediate or high risk CLL Intermediate risk CLL describes people with stage 1 to stage 2 CLL, according to the Rai system. People with stage 1 or 2 CLL have enlarged lymph nodes and potentially an enlarged spleen and liver but close to normal red blood cell and platelet counts. High risk CLL describes patients with stage 3 or stage 4 cancer. This means you may have an enlarged spleen, liver, or lymph nodes. Low red blood cell counts are also common. In the highest stage, platelet counts may be low as well. If you have intermediate or high risk CLL, your doctor will likely recommend that you start treatment right away. Chemotherapy and immunotherapy In the past, the standard treatment for CLL included a combination of chemotherapy and immunotherapy agents, such as: a combination of fludarabine and cyclophosphamide (FC) FC plus an antibody immunotherapy known as rituximab (Rituxan) for people younger than 65 bendamustine (Treanda) plus rituximab for people older than 65 chemotherapy in combination with other immunotherapies, such as alemtuzumab (Campath), obinutuzumab (Gazyva), and ofatumumab (Arzerra). These options may be used if the first round of treatment doesn't work. Targeted therapies Over the last few years, a better understanding of the biology of CLL has led to a number of more targeted therapies. These drugs are called targeted therapies because they're directed at specific proteins that help CLL cells grow. Examples of targeted drugs for CLL include: zanubrutinib (Brukinsa): Approved by the Food and Drug Administration (FDA) in 2023, zanubrutinib targets the enzyme known as Bruton's tyrosine kinase (BTK), which is crucial for CLL cell survival. ibrutinib (Imbruvica): This targets BTK with less precision than zanubrutinib. venetoclax (Venclexta): This used in combination with obinutuzumab (Gazyva), targets the BCL2 protein, a protein seen in CLL. idelalisib (Zydelig): This blocks the kinase protein known as PI3K and is used for relapsed CLL. duvelisib (Copiktra): This also targets PI3K but is typically used only after other treatments fail. acalabrutinib (Calquence): This is another BTK inhibitor approved in late 2019 for treating CLL. Monoclonal antibody therapies Monoclonal antibody therapies are a type of treatment in which proteins are made in a laboratory and designed to target certain antigens. They help jolt your immune system into attacking the cancer cells. There are several monoclonal antibody treatments approved for treating CLL by targeting the antigens CD20 and CD52: rituximab (Rituxan): targets CD20, often used with chemotherapy or targeted therapy as part of the initial treatment or in the second-line treatment obinutuzumab (Gazyva): targets CD20, used with venetoclax (Venclexta) or chlorambucil (Leukeran) for patients with previously untreated CLL ofatumumab (Arzerra): targets CD20, usually used in patients whose disease has not responded to prior treatments and is given in combination with chlorambucil (Leukeran) or FC alemtuzumab (Campath): targets CD52 Blood transfusions You may need to receive intravenous (IV) blood transfusions to increase blood cell counts. Radiation Radiation therapy uses high-energy particles or waves to help kill cancer cells and shrink painful, enlarged lymph nodes. Radiation therapy is rarely used in CLL treatment. Stem cell and bone marrow transplants Your doctor may recommend a stem cell transplant if your cancer doesn't respond to other treatments. A stem cell transplant allows you to receive higher doses of chemotherapy to kill more cancer cells. Higher doses of chemotherapy can cause damage to your bone marrow. To replace these cells, you'll need to receive additional stem cells or bone marrow from a healthy donor. Breakthrough treatments A large number of approaches are under investigation to treat people with CLL. Some have been recently approved by the FDA. Drug combinations In May 2019, the FDA approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) to treat people with previously untreated CLL as a chemotherapy-free option. In April 2020, the FDA approved a combination therapy of rituximab (Rituxan) and ibrutinib (Imbruvica) for adult patients with chronic CLL. These combinations make it more likely that people may be able to do without chemotherapy altogether in the future. Nonchemotherapy treatment regimens are essential for those who can't tolerate harsh chemotherapy-related side effects. CAR T-cell therapy One of the most promising future treatment options for CLL is CAR T-cell therapy. CAR T-cell therapy, which stands for chimeric antigen receptor T-cell therapy, uses a person's own immune system cells to fight cancer. The procedure involves extracting and altering a person's immune cells to better recognize and destroy cancer cells. The cells are then put back into the body to multiply and fight off the cancer. CAR T-cell therapy research is still ongoing. In September 2023, researchers reported a possible 'universal' CAR T-cell treatment that may be effective in all types of blood cancers. CAR T-cell therapies are promising, but they do carry risks. One risk is a condition called cytokine release syndrome. This is an inflammatory response caused by the infused CAR T-cells. Some people can experience severe reactions that may lead to death if not quickly treated. Other drugs under investigation Some other targeted drugs currently being evaluated in clinical trials for CLL include: entospletinib (GS-9973) tirabrutinib (ONO-4059 or GS-4059) cirmtuzumab (UC-961) ublituximab (TG-1101) pembrolizumab (Keytruda) nivolumab (Opdivo) Once clinical trials are completed, some of these drugs may be approved for treating CLL. Talk with a doctor about joining a clinical trial, especially if current treatment options aren't working for you. Clinical trials evaluate the efficacy of new drugs as well as combinations of already approved drugs. These new treatments may work better for you than the ones currently available. Hundreds of clinical trials are ongoing for CLL.
Medscape
24 minutes ago
- Medscape
Brief Use of CGM May Enhance Lifestyle Awareness in T2D
TOPLINE: Short-term use of continuous glucose monitoring (CGM) provided valuable insights into lifestyle factors affecting blood glucose levels in people with type 2 diabetes (T2D) who were not on insulin therapy, particularly in those with a diabetes duration of less than 5 years. METHODOLOGY: CGM is an effective strategy for managing blood glucose levels in people with non-insulin-treated T2D; this study focused on the insights gained regarding lifestyle factors affecting blood glucose levels over a 2-week period of usage. Participants with non-insulin-treated T2D across 20 cities in Denmark received a single CGM device during a walk-in setup, with minimal guidance provided during device installation. They used the CGM device for a maximum of 14 days. Baseline questionnaires were completed onsite, with follow-up surveys sent via email after 2 weeks and after 3 months. TAKEAWAY: A total of 724 participants completed the second questionnaire sent after 2 weeks. Of these, 80% found CGM highly useful and informative for managing T2D. Participants with a diabetes duration of less than 5 years engaged in more daily scans (80% vs 71%) and reported greater insights into the effects of lifestyle on glucose levels — including food (88% vs 78%), portion sizes (80% vs 60%), and physical activity (65% vs 55%) — than those with a diabetes duration of more than 5 years. Education level did not significantly affect the knowledge gained from CGM usage. At the 3-month follow-up, 50% of participants reported maintaining behavioral changes based on their CGM experience. IN PRACTICE: "These insights may encourage long-term behavioral changes, potentially leading to improved glycemic control," the authors wrote. SOURCE: The study was led by Emma Munch Nielsen, Glostrup, Denmark. It was presented by Tanja Thybo, Glostrup, Denmark, on June 20, 2025, at the 85th Scientific Sessions - American Diabetes Association, held at the McCormick Place Convention Center, Chicago. LIMITATIONS: No limitations were discussed in the abstract. DISCLOSURES: No funding details were disclosed. Three authors disclosed relationships with Abbott. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
